logo
Sign In
  1. Home
  2. Indications
  3. Gastrointestinal Stromal Tumors

Medications for Gastrointestinal Stromal Tumors

FiltersReset Filters
10 results

  • ayvakit

    (avapritinib)
    Medication Details
    Blueprint Medicines Corporation
    Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (IMATINIB MESYLATE)
    Medication Details
    Camber Pharmaceuticals, Inc.
    Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), blast crisis, and acute lymphoblastic leukemia (ALL) in adults and pediatrics, as well as for myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
    Medication Details

  • imatinib mesylate

    (Imatinib Mesylate)
    Medication Details
    Chartwell RX, LLC
    Usage: This drug is indicated for treatment of Philadelphia positive chronic myeloid leukemia (CML) in various phases, acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (Imatinib Mesylate)
    Medication Details
    Apotex Corp
    Usage: This drug is indicated for the treatment of newly diagnosed and resistant Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), various myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastro-intestinal stromal tumors (GIST).
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (Imatinib Mesylate)
    Medication Details
    BluePoint Laboratories
    Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (imatinib mesylate)
    Medication Details
    Archis Pharma LLC
    Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (imatinib mesylate)
    Medication Details
    Qilu Pharmaceutical Co., Ltd.
    Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.
    Medication Details
    Drug Interactions

  • imatinib mesylate

    (imatinib)
    Medication Details
    Mylan Pharmaceuticals Inc.
    Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
    Medication Details
    Drug Interactions

  • qinlock

    (Ripretinib)
    Medication Details
    Deciphera Pharmaceuticals, LLC
    Usage: QINLOCK is indicated for adult patients with advanced gastrointestinal stromal tumor (GIST) who have previously been treated with three or more kinase inhibitors, including imatinib.
    Medication Details
    Drug Interactions

  • sutent

    (Sunitinib malate)
    Medication Details
    U.S. Pharmaceuticals
    Usage: SUTENT is indicated for adult patients with gastrointestinal stromal tumor (GIST) post-imatinib treatment, advanced renal cell carcinoma (RCC), adjuvant therapy for high-risk recurrent RCC post-nephrectomy, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable or metastatic stages.
    Medication Details
    Drug Interactions
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.